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The Update is a bi-weekly 
Web newsletter published 
by the Iowa Department of 
Public Health’s Bureau of 
Family Health.  It is posted 
the second and fourth week 
of every month, and provides 
useful job resource information 
for departmental health care 
professionals, information 
on training opportunities, 
intradepartmental reports 
and meetings, and additional 
information pertinent to health 
care professionals.
Break the Silence: Stop the Violence
National Center for Injury Prevention and Control (NCIPC)
It may shock you to know that one out of 
every eleven teens reports being hit or 
physically hurt by a boyfriend or girlfriend 
in the past twelve months. But why is that, 
and how can we change it? In “Break 
The Silence: Stop the Violence,” parents 
talk with teens about developing healthy, 
respectful relationships before they start 
dating.
The Centers for Disease Control and 
Prevention has launched CDC-TV, a new 
online video resource available through 
www.cdc.gov. CDC-TV videos will cover a 
variety of health, safety and preparedness topics.
The premiere series on CDC-TV is “Health Matters.” The fi rst segment of 
the series, “Break the Silence: Stop the Violence,” addresses the topic of 
teen dating violence. In this video, parents and teens discuss the problem 
of dating violence and how to prevent it.
The library of available videos through CDC-TV will expand to include 
single-topic presentations as well as series for children, parents and public 
health professionals. Most are short and all include captioning for the 
hearing-impaired.
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Fire Prevention Safety in Iowa Child Care Centers
January  30 ,  2009,  10  a .m.  to  12  p .m. ,  ICN
Target Audience: 
Consultants working with the following programs:
Child Care Business owners/directors, Child Care Home Consultants, Child 
Care Licensing Consultants, Child Care Nurse Consultants, Community 
Empowerment Consultants, Early ACCESS Consultants, Early Childhood 
Educators, Head Start or Early Head Start Consultants, Iowa State University 
Extension Consultants, PITC Consultants, School Personnel, Shared Visions 
Consultants
Purpose: 
To keep consultants working with early childhood care and education businesses 
informed of fi re prevention and safety strategies and regulations.
For more information, go to page 7 of The Update.
Break the Silence: Stop the Violence continued 
Other videos include:
 Go with the Flow (CDC studies show that widespread water fl uoridation prevents cavities and saves money) 
 Personal Flu Stories: Why Flu Vaccination Matters
 Put Your Hands Together (Learn how to help stop the spread of infection and stay healthy. It’s easy when 
 you ‘Put Your Hands Together’)
 The Quiet Killer (Each year, nearly 500 die while as many as 20,000 visit emergency rooms for exposure  
 to carbon monoxide)
 Baby Steps: Learn the Signs. Act Early (CDC manages a campaign to help parents measure their   
 children’s development by how they play, learn, speak and act)
 A New Era of Preparedness (CDC efforts to assure preparedness for emerging health threats)
The videos are part of CDC′s efforts to increase access to information that can help people prevent illness 
and injury. “Online video is one of the best tools we have to reach a large number of people and help them 
make informed health decisions by providing accurate health information,” said Jay Bernhardt, Ph.D., director 
of CDC′s National Center for Health Marketing. “CDC-TV marks an exciting new chapter in our continuing 
efforts to provide CDC’s health information to the public when, where, and how they want it.”
The videos are available at www.cdc.gov/CDCtv. 
Bureau of Family Health Grantee Committee Meeting
The next Bureau of Family Health Grantee Committee will be scheduled during the 2009 Iowa Public 
Health Conference, April 7-8.  This is a required meeting for Bureau of Family Health contract agencies.  
P r o g r a m  M a n a g e m e n t
Healthy Start ,  Grow Smart 
The “Healthy Start, Grow Smart,” health education 
series is intended to improve early childhood education 
for America’s youngest children by providing easily 
understood information to parents and caregivers about 
best practices in early childhood development. 
“Healthy Smart, Grow Smart” offers several issues, one 
for the newborn and one for each of the fi rst 12 months 
of the new infant’s life. A 15-month, 18-month and 24-
month series is also available.  Published in English, 
Spanish, Vietnamese and Chinese, these booklets have 
been developed by health experts to provide valuable 
age-appropriate information about health, safety, 
nutritional needs and early cognitive development.
This is a tool you can provide to assist parents in raising 
healthy children, and it is absolutely free. You may order individual booklets or the entire series 
by visiting http://cms.ntis.gov.  The series is also available for download.
P r o g r a m  M a n a g e m e n t
2009 Immunization Schedules
On January 2, 2009, the Centers for Disease Control and Prevention (CDC) published the “Recommended 
Immunization Schedules for Persons Aged 0 through 18 Years-United States, 
2009” as endorsed by the CDC, AAP, and AAFP.  The Advisory Committee on 
Immunization Practices (ACIP) annually publishes immunization schedules that 
summarize recommendations for currently licensed vaccines for children aged 18 
years and younger.  Go to pages 9-11 of The Update to view the 2009 Schedules for 
Persons Aged 0-6 Years, Persons Ages 7-18 Years, and the Catch-Up Schedule.
Changes from the year’s previous schedule include:
 Recommendations for rotavirus vaccines include changes for the maximum  
 age for the fi rst dose (14 weeks 6 days) and the maximum age for any dose  
 (8 months 0 days). The rotavirus footnote also indicates that if RV1 (Rotarix)  
 is administered at ages 2 and 4 months, a dose at 6 months is not indicated. 
 Routine annual infl uenza vaccination is recommended for all children aged 6 months through 18 years.  
 Children aged younger than 9 years who are receiving infl uenza vaccine for the fi rst time or who were  
 vaccinated for the fi rst time during the previous season but only received 1 dose should receive 2 doses  
 of infl uenza vaccine at least 4 weeks apart. Healthy non-pregnant persons aged 2 through 49 years may  
 receive either live attenuated infl uenza vaccine or inactivated infl uenza vaccine. 
 The minimum interval between tetanus and diphtheria toxoids (Td) and tetanus and diphtheria toxoids  
 and acellular pertussis vaccine (Tdap) for persons aged 10 through 18 years is addressed. An interval  
 less than 5 years may be used if pertussis immunity is needed. 
 Information about the use of Haemophilus infl uenzae type b (Hib) conjugate vaccine among persons  
 aged 5 years and older at increased risk for invasive Hib disease has been added.  Use of Hib vaccine  
 for these persons is not contraindicated.  
 Catch-up vaccination with human papillomavirus (HPV) vaccine is clarifi ed. Routine dosing intervals  
 should be used for series catch-up (i.e., the second and third doses should be administered 2 and 6  
 months after the fi rst dose). The third dose should be given at least 24 weeks after the fi rst dose. 
 Abbreviations for rotavirus, pneumococcal polysaccharide, and meningococcal polysaccharide vaccines  
 have been changed.
 The National Childhood Vaccine Injury Act requires that healthcare providers provide parents or patients  
 with copies of Vaccine Information Statements before administering each dose of the vaccines listed in  
 the schedules.  Additional information is available from CDC at www.cdc.gov/vaccines/pubs/vis.
 continued on next page
P r o g r a m  M a n a g e m e n t
2009 Immunization Schedules continued
Detailed recommendations for using vaccines are available from ACIP statements available at 
www.cdc.gov/vaccines/pubs/acip-list.htm and the 2006 Red Book.  Guidance regarding the Vaccine Adverse 
Event Reporting System form is available at www.vaers.hhs.gov or by telephone at (800) 822-7967.  To 
access a ready-to-print (PDF) version of the issue of MMWR which contains the schedule, go to www.cdc.
gov/mmwr/PDF/wk/mm5751.pdf.  To access the “Recommended Immunization Schedules for Persons Aged 
0 through 18 Years – United States, 2009”, go to www.cdc.gov/vaccines/recs/schedules/default.htm.
Monthly CAReS and Child Health/EPSDT Training at IDPH
The Bureau of Family Health will be offering both CAReS and Child Health / EPSDT training during the 
months of March through November 2009. The CAReS training is the new user training. The EPSDT Part II 
training is the follow-up to the EPSDT Part I training that you have at your agency (video or CD ROM). 
The CAReS training will be held from 10:00 a.m. – 12:00 p.m. with the Part II:  EPSDT – Serving Iowa’s 
Children and Families training to follow from 12:30 p.m. – 4:00 p.m.  See the dates and Des Moines 
training locations below.  
 Tuesday, March 10, 2009 – Lucas State Offi ce Building, Conference Room 526 (Licensure Board Room)
 Thursday, April 16, 2009 – Lucas State Offi ce Building, Conference Room 523
 Thursday, May 28, 2009 – Lucas State Offi ce Building, Conference Room 517
 Thursday, June 25, 2009 – Hoover State Offi ce Building, A Level Conference Room #4 (inside the DAS  
 double doors and immediately to the right)
 Thursday, July 23, 2009 - Hoover State Offi ce Building, A Level Conference Room #4 (inside the DAS  
 double doors and immediately to the right)
 Thursday, August 27, 2009 - Lucas State Offi ce Building, Conference Room 517
 Thursday, September 24, 2009 - Hoover State Offi ce Building, A Level Conference Room #4 (inside the  
 DAS double doors and immediately to the right)
 Friday, October 23, 2009 - Lucas State Offi ce Building, Conference Room 517
 Thursday, November 12, 2009 - Lucas State Offi ce Building, Conference Room 517
Please e-mail Marcus Johnson or Janet Beaman with the names of staff from your agency that will attend on 
selected dates.  Specify which training each staff member will attend (CAReS or EPSDT Part II or both).  Also 
know that our space is limited.  If seating capacity fi lls, we may need to request that future dates be selected.
If you have questions, please contact: Marcus Johnson - mjohnson@idph.state.ia.us, (515) 242-6284; 
Janet Beaman - jbeaman@idph.state.ia.us, (515) 281-3052; Carol Hinton - chinton@idph.state.ia.us (515) 281-6924. 
W O R T H    N O T I N G 
CDC Health Advisory
The CDC continues to collaborate with public health offi cials in many states and the United States Food 
and Drug Administration (FDA) to investigate a multistate outbreak of human infections due to Salmonella 
serotype Typhimurium. As of 9 PM Wednesday, January 21, 2009, the case count is 488 in 43 states 
(includes Iowa) and one case in Canada. 
Please share the following information and resources with the public and other stakeholders through your 
channels and contacts:
In order to make it easier for consumers to determine whether any of the peanut butter-containing products 
they have at home are subject to recall, the Food and Drug Administration (FDA) has created and posted 
an expanded, searchable database that will be updated as new information becomes available.  This 
information is available at www.accessdata.fda.gov/scripts/peanutbutterrecall/index.cfm. 
For information on products containing peanut butter from companies not reporting recalls, consumers may 
wish to consult the company’s website or call the toll-free number listed on most packaging. Please note 
that information consumers may receive from the companies has not been verifi ed by FDA.
Information about recalled products and Salmonella can be found by calling 1-800-CDC-INFO.
A podcast on the outbreak, response, and consumer information can be downloaded from CDC’s Web site 
at www2a.cdc.gov/podcasts/player.asp?f=10684.
Persons who think they may have become ill from eating peanut butter are advised to consult their health 
care providers. Most persons infected with Salmonella develop diarrhea, fever, and abdominal cramps 
12–72 hours after infection. 
C A L E N D A R  O F  E V E N T S
February 10-11, 2009
Early Childhood Iowa Congress
Airport Holiday Inn, Des Moines
For more information, go to www.state.ia.us/earlychildhood/
ECI_Congress/index.html.
February 12, 2009
Early Childhood Iowa Day on the Hill
State Capitol, Des Moines
For more information, go to www.state.ia.us/earlychildhood/ECI_Congress/index.html.
*April 7-8, 2009
2009 Public Health Conference
Scheman Conference Center, Ames
For more information, contact Andrew Connet at (515) 281-7184 or aconnet@idph.state.ia.us.
*Required meeting
 
Bureau of Family Health:  1-800-383-3826 
Teen Line:  1-800-443-8336 
Healthy Families Line:  1-800-369-2229 
FAX:  515-242-6013 
 
NAME PHONE E-MAIL 
Beaman, Janet 281-3052 jbeaman@idph.state.ia.us 
Borst, M. Jane 
(Bureau Chief) 281-4911 jborst@idph.state.ia.us 
Brown, Kim 281-3126 kbrown@idph.state.ia.us 
Clausen, Sally 281-6071 sclausen@idph.state.ia.us 
Connet, Andrew 281-7184 aconnet@idph.state.ia.us 
Dhooge, Lucia 281-7613 ldhooge@idph.state.ia.us 
Doyle Scar, Angie 242-5980 adoyle@idph.state.ia.us 
Ellis, Melissa 281-7044 mellis@idph.state.ia.us 
Goebel, Patrick 281-3826 pgoebel@idph.state.ia.us 
Hageman, Gretchen 281-7585 ghageman@idph.state.ia.us 
Hinton, Carol 281-6924 chinton@idph.state.ia.us 
Hobert, Heather 281-6880 hhobert@idph.state.ia.us 
Hodges, Jenny 281-4926 jhodges@idph.state.ia.us 
Hummel, Brad 281-5401 bhummel@idph.state.ia.us 
Johnson, Marcus 242-6284 mjohnson@idph.state.ia.us 
Jones, Beth 281-7044 bjones@idph.state.ia.us 
Miller, Lindsay 281-7721 lmiller@idph.state.ia.us 
Monsma, Alison 281-7368 amonsma@idph.state.ia.us 
Montgomery, Juli 242-5593 jmontgom@idph.state.ia.us 
O’Hollearn, Tammy 242-5639 tohollea@idph.state.ia.us 
Pearson, Analisa 281-7519 apearson@idph.state.ia.us 
Peterson, Janet 242-6388 jpeterso@idph.state.ia.us 
Piper, Kim 281-6466 kpiper@idph.state.ia.us 
Schulte, Kelly 281-8284 kschulte@idph.state.ia.us 
Trusty, Stephanie 281-4731 strusty@idph.state.ia.us 
Wheeler, Denise 281-4907 dwheeler@idph.state.ia.us 
Area code is 515 
Recommended Immunization Schedule for Persons  Aged 0 Through 6 Years—United States • 2009
For those who fall behind or start late, see the catch-up schedule
Certain 
high-risk 
groups
Range of 
recommended 
ages 
This schedule indicates the recommended ages for routine administration 
of currently licensed vaccines, as of December 1, 2008, for children aged 
0 through 6 years. Any dose not administered at the recommended age 
should be administered at a subsequent visit, when indicated and feasible. 
Licensed combination vaccines may be used whenever any component 
of the combination is indicated and other components are not contraindicated 
and if approved by the Food and Drug Administration for that dose of 
the series. Providers should consult the relevant Advisory Committee on 
Immunization Practices statement for detailed recommendations, including 
high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. 
Clinically significant adverse events that follow immunization should 
be reported to the Vaccine Adverse Event Reporting System (VAERS). 
Guidance about how to obtain and complete a VAERS form is 
available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
Vaccine  Age  Birth 1month 2months 4months 6months 12months 15months 18months 19–23months 2–3years 4–6years
Hepatitis B1 HepB
see  
footnote1
Rotavirus2 RV RV RV
2
Diphtheria, Tetanus, Pertussis3 DTaP DTaP DTaP
see  
footnote3
Haemophilus influenzae type b4 Hib Hib Hib
4
Pneumococcal5 PCV PCV PCV
Inactivated Poliovirus IPV IPV
Influenza6
Measles, Mumps, Rubella7
Varicella8
Hepatitis A9
Meningococcal10
HepBHepB
DTaP DTaP
Hib
IPVIPV
MMR
VaricellaVaricella
MMR
see footnote8
see footnote7
PCV
  HepA (2 doses) HepA Series
MCV
Influenza (Yearly)
PPSV
1. Hepatitis B vaccine (HepB). (Minimum age: birth)
 At birth:
	 •		Administer	monovalent	HepB	to	all	newborns	before	hospital	discharge.
	 •		If	mother	is	hepatitis	B	surface	antigen	(HBsAg)-positive,	administer	HepB	
and	0.5	mL	of	hepatitis	B	immune	globulin	(HBIG)	within	12	hours	of	birth.
	 •		If	mother’s	HBsAg	status	is	unknown,	administer	HepB	within	12	hours	of	
birth.	Determine	mother’s	HBsAg	status	as	soon	as	possible	and,	if	 
HBsAg-positive,	administer	HBIG	(no	later	than	age	1	week).
 After the birth dose:
	 •		The	HepB	series	should	be	completed	with	either	monovalent	HepB	or	a	
combination	vaccine	containing	HepB.	The	second	dose	should	be	 
administered at age 1 or 2 months. The final dose should be administered 
no earlier than age 24 weeks.
	 •		Infants	born	to	HBsAg-positive	mothers	should	be	tested	for	HBsAg	and	
antibody	to	HBsAg	(anti-HBs)	after	completion	of	at	least	3	doses	of	the	
HepB	series,	at	age	9	through	18	months	(generally	at	the	next	well-child	visit).
 4-month dose:
	 •		Administration	of	4	doses	of	HepB	to	infants	is	permissible	when	combination 
vaccines	containing	HepB	are	administered	after	the	birth	dose.
2. Rotavirus vaccine (RV). (Minimum age: 6 weeks)
	 •		Administer	the	first	dose	at	age	6	through	14	weeks	(maximum	age:	 
14 weeks 6 days). Vaccination should not be initiated for infants aged  
15 weeks or older (i.e., 15 weeks 0 days or older).
	 •		Administer	the	final	dose	in	the	series	by	age	8	months	0	days.
	 •		If	Rotarix® is administered at ages 2 and 4 months, a dose at 6 months is 
not indicated.
3.  Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). 
(Minimum age: 6 weeks)
	 •		The	fourth	dose	may	be	administered	as	early	as	age	12	months,	provided	
at least 6 months have elapsed since the third dose.
	 •	Administer	the	final	dose	in	the	series	at	age	4	through	6	years.	
4.  Haemophilus influenzae type b conjugate vaccine (Hib).  
(Minimum age: 6 weeks)
	 •		If	PRP-OMP	(PedvaxHIB®	or	Comvax®	[HepB-Hib])	is	administered	at	ages	 
2 and 4 months, a dose at age 6 months is not indicated.
	 •		TriHiBit®	(DTaP/Hib)	should	not	be	used	for	doses	at	ages	2,	4,	or	6	months	
but can be used as the final dose in children aged 12 months or older.
5.  Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate 
vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV])
	 •		PCV	is	recommended	for	all	children	aged	younger	than	5	years.	
Administer 1 dose of PCV to all healthy children aged 24 through 59 
months who are not completely vaccinated for their age.
	 •		Administer	PPSV	to	children	aged	2	years	or	older	with	certain	underlying	
medical conditions (see MMWR	2000;49[No.	RR-9]),	including	a	cochlear	
implant.
6.  Influenza vaccine. (Minimum age: 6 months for trivalent inactivated  
influenza vaccine [TIV]; 2 years for live, attenuated influenza vaccine [LAIV])
	 •		Administer	annually	to	children	aged	6	months	through	18	years.
	 •		For	healthy	nonpregnant	persons	(i.e.,	those	who	do	not	have	underlying	
medical conditions that predispose them to influenza complications) aged 
2 through 49 years, either LAIV or TIV may be used.
	 •		Children	receiving	TIV	should	receive	0.25	mL	if	aged	6	through	35	months	
or	0.5	mL	if	aged	3	years	or	older.
	 •		Administer 2 doses (separated by at least 4 weeks) to children aged younger 
than 9 years who are receiving influenza vaccine for the first time or who 
were vaccinated for the first time during the previous influenza season but 
only received 1 dose.
7.  Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
	 •		Administer	the	second	dose	at	age	4	through	6	years.	However,	the	second 
dose may be administered before age 4, provided at least 28 days have 
elapsed since the first dose.
8. Varicella vaccine. (Minimum age: 12 months) 
	 •		Administer	the	second	dose	at	age	4	through	6	years.	However,	the	second 
dose	may	be	administered	before	age	4,	provided	at	least	3	months	have	
elapsed since the first dose.
	 •		For	children	aged	12	months	through	12	years	the	minimum	interval	
between	doses	is	3	months.	However,	if	the	second	dose	was	administered 
at least 28 days after the first dose, it can be accepted as valid.
9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
	 •		Administer	to	all	children	aged	1	year	(i.e.,	aged	12	through	23	months).	
Administer 2 doses at least 6 months apart.
	 •		Children	not	fully	vaccinated	by	age	2	years	can	be	vaccinated	at	 
subsequent visits.
	 •		HepA	also	is	recommended	for	children	older	than	1	year	who	live	in	areas	
where vaccination programs target older children or who are at increased 
risk of infection. See MMWR 2006;55(No. RR-7). 
10.  Meningococcal vaccine. (Minimum age: 2 years for meningococcal conjugate 
vaccine [MCV] and for meningococcal polysaccharide vaccine [MPSV])  
	 •		Administer	MCV	to	children	aged	2	through	10	years	with	terminal	complement 
component deficiency, anatomic or functional asplenia, and certain other 
high-risk groups. See MMWR 2005;54(No. RR-7).
	 •		Persons	who	received	MPSV	3	or	more	years	previously	and	who	remain	
at	increased	risk	for	meningococcal	disease	should	be	revaccinated	with	MCV.
The Recommended Immunization Schedules for Persons Aged 0 Through 18 Years are approved by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/recs/acip),
the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org). CS
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The Recommended Immunization Schedules for Persons Aged 0 Through 18 Years are approved by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/recs/acip),
the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org).
Recommended Immunization Schedule for Persons  Aged 7 Through 18 Years—United States • 2009
For those who fall behind or start late, see the schedule below and the catch-up schedule
This schedule indicates the recommended ages for routine administration 
of currently licensed vaccines, as of December 1, 2008, for children aged 
7 through 18 years. Any dose not administered at the recommended age 
should be administered at a subsequent visit, when indicated and feasible. 
Licensed combination vaccines may be used whenever any component of 
the combination is indicated and other components are not contraindicated 
and if approved by the Food and Drug Administration for that dose of 
the series. Providers should consult the relevant Advisory Committee on 
Immunization Practices statement for detailed recommendations, including 
high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. 
Clinically significant adverse events that follow immunization should 
be reported to the Vaccine Adverse Event Reporting System (VAERS). 
Guidance about how to obtain and complete a VAERS form is 
available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
C
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1.  Tetanus and diphtheria toxoids and acellular pertussis vaccine 
(Tdap). (Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL®)
  •  Administer at age 11 or 12 years for those who have completed the 
recommended childhood DTP/DTaP vaccination series and have 
not received a tetanus and diphtheria toxoid (Td) booster dose.
 •  Persons aged 13 through 18 years who have not received Tdap 
should receive a dose.
 •  A 5-year interval from the last Td dose is encouraged when Tdap is 
used as a booster dose; however, a shorter interval may be used if 
pertussis immunity is needed.
2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years) 
 •  Administer the first dose to females at age 11 or 12 years. 
 •  Administer the second dose 2 months after the first dose and the 
third dose 6 months after the first dose (at least 24 weeks after the 
first dose). 
 •  Administer the series to females at age 13 through 18 years if not 
previously vaccinated.
3. Meningococcal conjugate vaccine (MCV).
 •  Administer at age 11 or 12 years, or at age 13 through 18 years if 
not previously vaccinated.
 •  Administer to previously unvaccinated college freshmen living in  
a dormitory. 
 •  MCV is recommended for children aged 2 through 10 years with 
terminal complement component deficiency, anatomic or functional 
asplenia, and certain other groups at high risk. See MMWR 
2005;54(No. RR-7).
 •  Persons who received MPSV 5 or more years previously and 
remain at increased risk for meningococcal disease should be 
revaccinated with MCV.
4. Influenza vaccine. 
 •  Administer annually to children aged 6 months through 18 years.
 •  For healthy nonpregnant persons (i.e., those who do not have 
underlying medical conditions that predispose them to influenza 
complications) aged 2 through 49 years, either LAIV or TIV may be used.
 •  Administer 2 doses (separated by at least 4 weeks) to children aged 
younger than 9 years who are receiving influenza vaccine for the 
first time or who were vaccinated for the first time during the previous 
influenza season but only received 1 dose.
5. Pneumococcal polysaccharide vaccine (PPSV). 
 •  Administer to children with certain underlying medical conditions 
(see MMWR 1997;46[No. RR-8]), including a cochlear implant.  
A single revaccination should be administered to children with 
functional or anatomic asplenia or other immunocompromising 
condition after 5 years.
6. Hepatitis A vaccine (HepA). 
 •  Administer 2 doses at least 6 months apart. 
 •  HepA is recommended for children older than 1 year who live in 
areas where vaccination programs target older children or who are 
at increased risk of infection. See MMWR 2006;55(No. RR-7).
7. Hepatitis B vaccine (HepB).
 •  Administer the 3-dose series to those not previously vaccinated.
 •  A 2-dose series (separated by at least 4 months) of adult formulation 
Recombivax HB® is licensed for children aged 11 through 15 years.
8. Inactivated poliovirus vaccine (IPV). 
 •  For children who received an all-IPV or all-oral poliovirus (OPV) series, 
a fourth dose is not necessary if the third dose was administered at 
age 4 years or older.
 •  If both OPV and IPV were administered as part of a series, a total of 
4 doses should be administered, regardless of the child’s current age. 
9. Measles, mumps, and rubella vaccine (MMR). 
 •  If not previously vaccinated, administer 2 doses or the second dose 
for those who have received only 1 dose, with at least 28 days 
between doses. 
10. Varicella vaccine. 
 •  For persons aged 7 through 18 years without evidence of immunity 
(see MMWR 2007;56[No. RR-4]), administer 2 doses if not previously 
vaccinated or the second dose if they have received only 1 dose.
 •  For persons aged 7 through 12 years, the minimum interval 
between doses is 3 months. However, if the second dose was 
administered at least 28 days after the first dose, it can be accepted 
as valid.
 •  For persons aged 13 years and older, the minimum interval 
between doses is 28 days.
Catch-up 
immunization
Range of 
recommended 
ages 
Vaccine  Age  7–10 years 11–12 years 13–18 years
Tetanus, Diphtheria,  Pertussis1 see footnote 1
Human Papillomavirus2 see footnote 2
Meningococcal3
Influenza4
Pneumococcal5
Hepatitis A6
Hepatitis B7
Inactivated Poliovirus8
Measles, Mumps, Rubella9
Varicella10
Tdap
HPV (3 doses)
MCV
HepB Series
MMR Series
IPV Series
Varicella Series
PPSV
Influenza (Yearly)
HepA Series
MCV
Certain 
high-risk 
groups
HPV Series
Tdap
MCV
The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine 
series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age.
Catch-up Immunization Schedule for Persons Aged 4 Months Through 18 Years  
Who Start Late or Who Are More Than 1 Month Behind—United States • 2009
Information about reporting reactions after immunization is available online at http://www.vaers.hhs.gov or by telephone, 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, 
including precautions and contraindications for immunization, is available from the National Center for Immunization and Respiratory Diseases at  http://www.cdc.gov/vaccines or telephone, 800-CDC-INFO (800-232-4636).
CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS THROUGH 6 YEARS
Vaccine Minimum Age  for Dose 1
Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
Hepatitis B1 Birth 4 weeks 8 weeks (and at least 16 weeks after first dose)
Rotavirus2 6 wks 4 weeks 4 weeks2
Diphtheria, Tetanus, Pertussis3 6 wks 4 weeks 4 weeks 6 months 6 months3
Haemophilus  
influenzae type b4 6 wks
4 weeks4
if current age is younger than 12 months
8 weeks (as final dose)4
if current age is 12 months or older and
second dose administered at younger than  
age 15 months
No further doses needed
if previous dose administered at age  
15 months or older
8 weeks (as final dose)
This dose only necessary for  
children aged 12 months through  
59 months who received 3 doses 
before age 12 months
Pneumococcal5 6 wks
4 weeks
if first dose administered at younger than  
age 12 months 
8 weeks 
(as final dose for healthy children)
if first dose administered at age 12 months or 
older or current age 24 through 59 months
No further doses needed
for healthy children if first dose administered 
at age 24 months or older
4 weeks
if current age is younger than 12 months
8 weeks 
(as final dose for healthy children)
if current age is 12 months or older
No further doses needed
for healthy children if previous dose  
administered at age 24 months or older
8 weeks (as final dose)
This dose only necessary for  
children aged 12 months through  
59 months who received 3 doses  
before age 12 months or for  
high-risk children who received  
3 doses at any age
Inactivated Poliovirus6 6 wks 4 weeks 4 weeks 4 weeks6
Measles, Mumps, Rubella7 12 mos 4 weeks
Varicella8 12 mos 3 months
Hepatitis A9 12 mos 6 months
Tetanus,Diphtheria/ 
Tetanus,Diphtheria, 
Pertussis10
7 yrs10 4 weeks
4 weeks 
if first dose administered at younger than 
age 12 months
6 months
if first dose administered at age 12 months or older
6 months
if first dose administered at  
younger than age 12 months
Human Papillomavirus11 9 yrs
Hepatitis A9 12 mos 6 months
Hepatitis B1 Birth 4 weeks 8 weeks (and at least 16 weeks after first dose)
Inactivated Poliovirus6 6 wks 4 weeks 4 weeks 4 weeks6
Measles, Mumps, Rubella7 12 mos 4 weeks
Varicella8 12 mos
3 months
if the person is younger than age 13 years
4 weeks
if the person is aged 13 years or older
Department of Health and Human Services  •  Centers for Disease Control and Prevention
1. Hepatitis B vaccine (HepB).
	 •		Administer	the	3-dose	series	to	those	not	previously	vaccinated.	
	 •		A	2-dose	series	(separated	by	at	least	4	months)	of	adult	formulation	Recombivax	HB® is licensed 
for children aged 11 through 15 years. 
2. Rotavirus vaccine (RV). 
	 •		The	maximum	age	for	the	first	dose	is	14	weeks	6	days.	Vaccination	should	not	be	initiated	for	
infants aged 15 weeks or older (i.e., 15 weeks 0 days or older).
	 •	Administer	the	final	dose	in	the	series	by	age	8	months	0	days.
	 •	If	Rotarix® was administered for the first and second doses, a third dose is not indicated.
3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). 
	 •	The	fifth	dose	is	not	necessary	if	the	fourth	dose	was	administered	at	age	4	years	or	older.
4. Haemophilus influenzae type b conjugate vaccine (Hib). 
	 •		Hib	vaccine	is	not	generally	recommended	for	persons	aged	5	years	or	older.	No	efficacy	data	are	
available	on	which	to	base	a	recommendation	concerning	use	of	Hib	vaccine	for	older	children	and	
adults.	However,	studies	suggest	good	immunogenicity	in	persons	who	have	sickle	cell	disease,	
leukemia,	or	HIV	infection,	or	who	have	had	a	splenectomy;	administering	1	dose	of	Hib	vaccine	to	
these persons is not contraindicated.
	 •		If	the	first	2	doses	were	PRP-OMP	(PedvaxHIB®	or	Comvax®), and administered at age 11 months 
or younger, the third (and final) dose should be administered at age 12 through 15 months and at 
least	8	weeks	after	the	second	dose.
	 •		If	the	first	dose	was	administered	at	age	7	through	11	months,	administer	2	doses	separated	by	4	
weeks and a final dose at age 12 through 15 months. 
5. Pneumococcal vaccine.
	 •		Administer	1	dose	of	pneumococcal	conjugate	vaccine	(PCV)	to	all	healthy	children	aged	24	through	
59	months	who	have	not	received	at	least	1	dose	of	PCV	on	or	after	age	12	months.
	 •		For	children	aged	24	through	59	months	with	underlying	medical	conditions,	administer	1	dose	
of	PCV	if	3	doses	were	received	previously	or	administer	2	doses	of	PCV	at	least	8	weeks	apart	if	
fewer than 3 doses were received previously.
	 •		Administer	pneumococcal	polysaccharide	vaccine	(PPSV)	to	children	aged	2	years	or	older	with	cer-
tain underlying medical conditions (see MMWR	2000;49[No.	RR-9]),	including	a	cochlear	implant,	
at	least	8	weeks	after	the	last	dose	of	PCV.
6. Inactivated poliovirus vaccine (IPV). 
	 •		For	children	who	received	an	all-IPV	or	all-oral	poliovirus	(OPV)	series,	a	fourth	dose	is	not	 
necessary if the third dose was administered at age 4 years or older. 
	 •		If	both	OPV	and	IPV	were	administered	as	part	of	a	series,	a	total	of	4	doses	should	be	administered,	
regardless of the child’s current age. 
7. Measles, mumps, and rubella vaccine (MMR). 
	 •		Administer	the	second	dose	at	age	4	through	6	years.	However,	the	second	dose	may	be	 
administered	before	age	4,	provided	at	least	28	days	have	elapsed	since	the	first	dose.	
	 •	If	not	previously	vaccinated,	administer	2	doses	with	at	least	28	days	between	doses.	
8. Varicella vaccine.
	 •		Administer	the	second	dose	at	age	4	through	6	years.	However,	the	second	dose	may	be	 
administered before age 4, provided at least 3 months have elapsed since the first dose.
	 •		For	persons	aged	12	months	through	12	years,	the	minimum	interval	between	doses	is	3	months.	
However,	if	the	second	dose	was	administered	at	least	28	days	after	the	first	dose,	it	can	be	
accepted as valid.
	 •		For	persons	aged	13	years	and	older,	the	minimum	interval	between	doses	is	28	days.
9. Hepatitis A vaccine (HepA).
	 •		HepA	is	recommended	for	children	older	than	1	year	who	live	in	areas	where	vaccination	programs	
target older children or who are at increased risk of infection. See MMWR	2006;55(No.	RR-7).	
10.  Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria 
toxoids and acellular pertussis vaccine (Tdap).
	 •		Doses	of	DTaP	are	counted	as	part	of	the	Td/Tdap	series
	 •		Tdap	should	be	substituted	for	a	single	dose	of	Td	in	the	catch-up	series	or	as	a	booster	for	children	
aged	10	through	18	years;	use	Td	for	other	doses.	
11. Human papillomavirus vaccine (HPV). 
	 •	Administer	the	series	to	females	at	age	13	through	18	years	if	not	previously	vaccinated.
	 •		Use	recommended	routine	dosing	intervals	for	series	catch-up	(i.e.,	the	second	and	third	doses	
should	be	administered	at	2	and	6	months	after	the	first	dose).	However,	the	minimum	interval	
between the first and second doses is 4 weeks. The minimum interval between the second and 
third doses is 12 weeks, and the third dose should be given at least 24 weeks after the first dose.
C
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4 weeks
if first dose administered at younger than
age 12 months
8 weeks (as final dose)
if first dose administered at age 12-14 months
No further doses needed
if first dose administered at age  
15 months or older
Routine dosing intervals are recommended11
CATCH-UP SCHEDULE FOR PERSONS AGED 7 THROUGH 18 YEARS
